ArticleClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2026
Effectiveness of Naltrexone and Baclofen Combination in Reducing Craving among Patients with Alcohol Dependence: An Open-label Trial.
Article in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Alcohol use disorder is among the most prevalent mental disorders worldwide. Craving, a key feature of alcohol dependence, is also a major reason for relapse. We aimed to determine the efficacy of naltrexone, baclofen, and naltrexone-baclofen combination in reducing craving among patients with alcohol dependence. Methods: In this open-label, randomised trial of eight weeks duration, 97 participants were randomly allocated to three groups, namely naltrexone alone, baclofen alone, and naltrexone-baclofen combination, using a computer-generated random number table. The dosage was 40 to 60 mg/day for baclofen and 50 mg a day for naltrexone. Tools used for assessment included the Obsessive Compulsive Drinking Scale (OCDS), the visual analogue scale (VAS) for craving, World Health Organization Quality of Life BREF (WHOQoL BREF), and World Health Organization Well-being Scale (WHO-5). Mixed design ANOVA was used for analysis. Results: The naltrexone-baclofen combination group had a significantly greater decline in OCDS score as compared to the naltrexone group, but not as compared to the baclofen alone group. Also, there was a greater reduction in VAS, WHOQoL BREF, and WHO-5 score in the naltrexone-baclofen group compared to the other two groups; however, the difference was not significant. No significant differences were found in relapse rates and heavy episodic drinking between groups. Conclusion: The naltrexone-baclofen combination may be better in comparison to naltrexone used alone in reducing craving in alcohol dependence and is well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.